002688.SHE Jinhe Biotechnology Co Ltd
- Market cap
- CNY 3.84B
- P/E
- 153.0x
- P/B
- 1.47x
- ROE
- 6.8%
- Dividend yield
- 3.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002688.SHE undervalued?
Graham numberThe Graham number of Jinhe Biotechnology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jinhe Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Jinhe Biotechnology Co Ltd yet.
Jinhe Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of pet food; sales of food additives; and raw materials. In addition, the company provides chlortetracycline, oxytetracycline, and other formulations. The company was founded in 1990 and is headquartered in Hohhot, China.
Full company profileJinhe Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jinhe Biotechnology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.50B | 1.46B | 1.63B | 1.78B | 1.81B | 2.08B | 2.12B | 2.17B | 2.37B | 2.88B | 2.79B |
| Gross Profit | 485M | 535M | 591M | 623M | 598M | 606M | 577M | 603M | 730M | 974M | 1.02B |
| Operating Income | 209M | 148M | 197M | 176M | 129M | 140M | 121M | 105M | 98.6M | 338M | 366M |
| EBITDA | 298M | 260M | 334M | 384M | 324M | 328M | 307M | 335M | 277M | 364M | 330M |
| Net Income | 164M | 108M | 164M | 185M | 117M | 94.0M | 75.6M | 86.5M | 100M | 27.6M | 177M |
| EPS | 0.26 | 0.17 | 0.26 | 0.29 | 0.18 | 0.14 | 0.10 | 0.11 | 0.13 | 0.04 | 0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 2.66B | 2.96B | 3.34B | 3.34B | 3.38B | 4.06B | 4.51B | 5.45B | 5.65B | 5.52B | 5.82B |
| Total Liabilities | 1.08B | 1.32B | 1.56B | 1.54B | 1.63B | 1.37B | 2.08B | 2.94B | 3.15B | 3.08B | 3.01B |
| Shareholders' Equity | 1.50B | 1.53B | 1.68B | 1.68B | 1.61B | 2.44B | 2.22B | 2.25B | 2.25B | 2.23B | 2.59B |
| Cash & Short-term Investments | 239M | 345M | 492M | 362M | 315M | 518M | 491M | 609M | 636M | 618M | 842M |
| Total Debt | 524M | 891M | 1.19B | 1.20B | 1.33B | 1.01B | 1.60B | 2.21B | 2.02B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 292M | 27.3M | 117M | 282M | 258M | 153M | 124M | 199M | 498M | 469M | - |
| Capital Expenditure | 129M | 197M | 170M | 179M | 204M | 384M | 402M | 457M | 362M | 320M | 359M |
| Free Cash Flow | 164M | -169M | -53.0M | 103M | 54.1M | -231M | -278M | -258M | 136M | 149M | 187M |
| Ratios | |||||||||||
| ROE | 11.0% | 7.1% | 9.8% | 11.0% | 7.3% | 3.9% | 3.4% | 3.8% | 4.5% | 1.2% | 6.8% |
| ROA | 6.2% | 3.7% | 4.9% | 5.5% | 3.5% | 2.3% | 1.7% | 1.6% | 1.8% | 0.5% | 3.1% |
| Net Profit Margin | 11.0% | 7.4% | 10.0% | 10.4% | 6.5% | 4.5% | 3.6% | 4.0% | 4.2% | 1.0% | 6.4% |
| Debt to Equity | 0.35x | 0.58x | 0.71x | 0.71x | 0.83x | 0.41x | 0.72x | 0.98x | 0.90x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jinhe Biotechnology Co Ltd dividends
- Dividend yield
- 3.85%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 536.5%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 148M | 0.19 | 536.5% |
| 2024 | CNY 161M | 0.21 | 160.6% |
| 2023 | CNY 149M | 0.19 | 172.0% |
| 2022 | CNY 40.5M | 0.05 | 53.6% |
| 2021 | CNY 63.5M | 0.09 | 67.6% |
| 2020 | CNY 159M | 0.24 | 135.4% |
| 2019 | CNY 159M | 0.25 | 85.9% |
| 2018 | CNY 65.1M | 0.10 | 39.8% |
| 2017 | CNY 142M | 0.22 | 130.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on May 17, 2016.
Who owns Jinhe Biotechnology Co Ltd
- Insiders 34.05%
- Institutions 2.25%
- Public & others 63.70%
- Shares outstanding 837M
- Free float 479M
Jinhe Biotechnology Co Ltd company profile
- Company name
- Jinhe Biotechnology Co Ltd
- Ticker
- 002688.SHE
- ISIN
- CNE100001HK7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 13, 2012
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,713
- Fiscal year end
- December
- Address
- No. 71, Xinping Road, Hohhot, China, 010200
- Phone
- 86 47 1655 5551
- Website
- jinhe.com.cn
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of pet food; sales of food additives; and raw materials. In addition, the company provides chlortetracycline, oxytetracycline, and other formulations. The company was founded in 1990 and is headquartered in Hohhot, China.
Jinhe Biotechnology Co Ltd management
10- Mr. Changxian XieGM & Director · born 1962
- Mr. You Shan NiuFinancial Director · born 1971
- Mr. Zhi Jun WangDeputy GM & Director · born 1974
- Mr. Manman LuAssistant to Chairman of Board, Board Secretary & Director · born 1973
- Mr. Ying Chun LiuDeputy General Manager · born 1967
- Mr. Yingzhen GuanDeputy General Manager · born 1964
- Mr. Xibao YunDeputy General Manager · born 1967
- Mr. Cheng Min GuoDeputy General Manager · born 1984
- Lihang ZhouChief Accounting Officer
- Mr. Mingsheng JianDeputy General Manager · born 1966